Get complete coverage of ACR Convergence 2022 here. Plus, explore our Gout, Axial Spondyloarthritis and Psoriatic Arthritis Resource Centers for research reviews, case reports and clinical articles on advances in the diagnosis and management of these conditions.
Focused Content
Gout Resource Center
Explore our coverage of the top research and additional gout information presented at ACR Convergence 2021 and much more.
[View]Axial Spondyloarthritis Resource Center
Explore our coverage of the top research in axial spondyloarthritis, additional information
[View]
presented at ACR Convergence 2022 and much more.Psoriatic Arthritis in Focus
Explore our coverage of the top research in psoriatic arthritis and additional information presented at ACR Convergence 2022 and much more.
[View]
Previous ACR Meetings
- ACR Convergence 2021
- ACR Convergence 2020
- 2019 ACR/ARP Annual Meeting
- 2018 ACR/ARHP Annual Meeting
- 2017 ACR/ARHP Annual Meeting
- 2016 ACR/ARHP Annual Meeting
- 2015 ACR/ARHP Annual Meeting
- 2014 ACR/ARHP Annual Meeting
- 2011 ACR/ARHP Annual Meeting
- 2010 ACR/ARHP Annual Scientific Meeting
- 2006 ACR Annual Meeting
- ACR/ARHP Annual Meeting
- Annual Meeting
Complete Coverage

COVID-19: Strategies to Protect Adult & Pediatric Patients
An ACR Convergence 2022 session provided practical updates on ways to best protect pediatric & adult patients with rheumatic disease from COVID-19.... [Read More]

Patients Living with Chronic Illness
At ACR Convergence 2022, three women with rheumatic diseases discuss the profound life changes that the diseases wrought and ways they’ve found to cope.... [Read More]

Clinical Rheumatology Year in Review—2022
In this overview of clinical updates in rheumatology in the last year, high-impact studies were discussed, including the GLORIA, ORAL Surveillance and MIRROR trials.... [Read More]

A Shot of Wisdom: Vaccinations in Patients with Rheumatic Disease
PHILADELPHIA—The treatment of rheumatic diseases is often a double-edged sword: immunosuppressive regimens can be very effective in reducing disease activity, but the cost of such treatments may be seen in the form of increased risk of infection. At ACR Convergence 2022, the session titled ACR Guidelines for Vaccination in Patients with Rheumatic and Musculoskeletal Diseases… [Read More]

Patients Fight Against Dark Days & Find Ways to Cope
PHILADELPHIA—Amy Gietzen started feeling the pain when she was 19. Her forearms, elbows, wrists and fingers were constantly swollen and sensitive. Six months later, she saw a doctor and was diagnosed with systemic diffuse scleroderma—a particularly hard-to-manage rheumatic disease with wide-ranging effects. Ms. Gietzen, who spoke at ACR Convergence 2022 and is a public speaker,… [Read More]

Rheumatic Disease Research in Indigenous Populations
This ACR Convergence 2022 session focused on ways to improve health equity in Indigenous populations.... [Read More]

Evolution of Medicare’s Merit-Based Incentive Payment System: MIPS Value Pathways
In November, the CMS finalized 12 MIPS Value Pathways (MVP) in the Quality Payment Program, including a rheumatology MVP. In 2023, clinicians can opt to report via traditional MIPS, the rheumatology MVP or both.... [Read More]

Understaffed, Over-Scrutinized & Feeling Powerless? ACR Advocacy Can Help
Elizabeth “Blair” Solow, MD, MSc, and Angus Worthing, MD, FACP, FACR, described the top political issues affecting rheumatology now and how ACR members can work toward practices and policies that help us better care for patients.... [Read More]

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022
PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel… [Read More]

New Findings for Polymyalgia Rheumatica & Osteoarthritis
The Plenary III Session reviewed the results of the SAPHYR trial of sarilumab in PMR patients, as well as the WE-CAN study on the impact of a community-level diet & exercise program on knee pain in patients with knee osteoarthritis.... [Read More]